Chris Francis - 08 Dec 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
SVP, Corporate Development, Head of Emerging Areas
Signature
/s/ Chris Francis
Issuer symbol
WVE
Transactions as of
08 Dec 2025
Transactions value $
-$4,319,902
Form type
4
Filing time
10 Dec 2025, 21:45:07 UTC
Previous filing
06 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Francis Chris SVP, Corporate Development, Head of Emerging Areas C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Chris Francis 10 Dec 2025 0001657709

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Options Exercise $88.3K +28.1K +112.5% $3.14 53.1K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$408K -28.1K -52.94% $14.50 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $416K +107K +429.6% $3.87 132K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$1.56M -107K -81.12% $14.56 25K 08 Dec 2025 Direct F1, F4
transaction WVE Ordinary Shares Options Exercise $218K +45.9K +183.53% $4.75 70.9K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$665K -45.9K -64.73% $14.50 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $29.4K +9.38K +37.5% $3.14 34.4K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$141K -9.38K -27.27% $15.00 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $118K +37.5K +150% $3.14 62.5K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$528K -37.5K -60% $14.08 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $69.3K +17.9K +71.6% $3.87 42.9K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$269K -17.9K -41.72% $15.00 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $581K +122K +489.4% $4.75 147K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$1.74M -122K -83.03% $14.20 25K 08 Dec 2025 Direct F1, F6
transaction WVE Ordinary Shares Options Exercise $524K +50K +200% $10.48 75K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$800K -50K -66.67% $16.00 25K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $63.7K +22.5K +90% $2.83 47.5K 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale -$317K -22.5K -47.37% $14.08 25K 08 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Options Exercise $0 -75K -88.89% $0.00 9.38K 08 Dec 2025 Ordinary Shares 75K $3.14 Direct F2
transaction WVE Share Option (right to buy) Options Exercise $0 -125K -43.75% $0.00 161K 08 Dec 2025 Ordinary Shares 125K $3.87 Direct F3
transaction WVE Share Option (right to buy) Options Exercise $0 -168K -68.75% $0.00 76.5K 08 Dec 2025 Ordinary Shares 168K $4.75 Direct F5
transaction WVE Share Option (right to buy) Options Exercise $0 -50K -100% $0.00 0 08 Dec 2025 Ordinary Shares 50K $10.48 Direct F7
transaction WVE Share Option (right to buy) Options Exercise $0 -22.5K -100% $0.00 0 08 Dec 2025 Ordinary Shares 22.5K $2.83 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
F2 The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
F3 The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
F4 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F5 The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
F6 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F7 These share options are fully vested.

Remarks:

SVP, Corporate Development, Head of Emerging Areas